CTRI/2012/08/002915已完成4 期
Assessment of Various Second Line Treatment Regimens on Mild to Moderate Persistent Asthmatic Patients
Dr K Ilango0 个研究点目标入组 242 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 242
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients with mild to moderate persistent asthma and Patients who give their informed consent for the study will be included
排除标准
- •ï??Patients with clinically significant renal, respiratory (other than asthma) cardiac, gastrointestinal, hepatic, endocrine disorders, hematological disorders, cancer or any other concurrent illness or patients who had undergone major surgery
- •ï??Patients who had unresolved upper respiratory tract infection within past three weeks of the pre study visit
- •ï??Participants who have received steroid during the month prior to the study
- •ï??Patients who were known or suspected hypersensitivity to study therapy or excipients
- •ï??Patients unwilling to give informed consent
- •ï??Pregnancy and lactating women
研究者
相似试验
进行中（未招募）
1 期
TRIAL TO EVALUATE CHEMOTHERAPY WITH CAPECITABINE OR CAPECITABINE PLUS MITOMYCIN C IN ADVANCED BILIARY TRACT CANCEREUCTR2011-002002-70-ITFONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR57
进行中（未招募）
1 期
Comprehensive Evaluation of Two Second-Line Therapeutic Approaches for Immune Thrombocytopenia (ITP) – a Pragmatic Randomized Controlled Trial - Holistic StudyImmune Thrombocytopenia (ITP)MedDRA version: 23.0Level: LLTClassification code: 10023095Term: ITP Class: 10005329CTIS2023-505573-32-00Ostfold Hospital Trust220
进行中（未招募）
1 期
Randomised study for second line treatment with nal-IRI and S1 in pancreatic cancer.pancreatic cancerEUCTR2017-004675-31-NLAcademic Medical Center120
进行中（未招募）
2 期
A randomized phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer who failed on first line gemcitabine-based chemotherapy2023-509463-24-01Amsterdam UMC146
进行中（未招募）
1 期
Randomised study for second line treatment with nal-IRI and S1 in pancreatic cancer.pancreatic cancerEUCTR2017-004675-31-ATAcademic Medical Center120